 |
인쇄하기
취소
|
Bayer urged to restart compassionate use program of Kogenate
A local hemophiliac group has called for Bayer to re-initiate their compassionate use program of Kogenate FS, antihemophilic factor (recombinant) for 21 Korean patients.
Kogenate is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. The drug is also indicated fo...
Kogenate is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. The drug is also indicated fo...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.